MetaCap

Anixa Biosciences Inc. (ANIX)

NASDAQ: ANIXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

2.44-0.16 (-6.15%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ANIX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$84.82M
EPS (TTM)
-$0.32
52-week range
2.32 – 5.46
Day range
2.40 – 2.59
Volume / Avg
355.05K / 282.29K
Beta
—

52-week range

$2.32$5.46

ANIX stock today

Shares of Anixa Biosciences (ANIX) finished lower on Nov 20 at $2.44, a drop of 6.15% or $0.16 per share, versus the S&P 500's 3.70% decline. At this level, ANIX sits near the bottom of its 52-week range of $2.32 to $5.46: 55.3% below the high, set on Dec 9, 2025 and 5.2% above the low. ANIX is down 21.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 43.8%.

Anixa Biosciences has posted a net loss over the last twelve months (EPS of -$0.32), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Anixa Biosciences

Company profile

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged in the development of a vaccine against breast cancer; and the development of a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Amit Kumar Ph.D.
Headquarters
San Jose, CA
Employees
4
Website
anixa.com

Financial highlights

Full financials

Anixa Biosciences reported a net loss of $10.9 million, compared with a loss of $12.6 million a year earlier. Diluted earnings per share came in at -$0.34.

Anixa Biosciences annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2022
Revenue—$210.00K$210.00K—$512.00K
Growth—0.00%———
Net income$-10.93M$-12.55M$-9.81M$-13.60M$-12.95M
EPS (diluted)$-0.34$-0.39$-0.32$0.45$-0.45

Analyst forecast

Forecast

Consensus (3 analysts)

strong_buy

Avg. price target

$9.67+296.31%

  • Strong buy 1
  • Buy 2
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $6.00High $14.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Q3 2026)
Sep 9, 2026
EPS actual vs est.
$-0.08 vs —

ANIX news

All ANIX news

Anixa Biosciences peers

Health Care sector
ANIX peer companies
CompanyPrice% ChgMarket capCompare
UPBUpstream Bio Inc.1.59-20.50%$87.15Mvs ANIX
EQEquillium Inc.1.06-5.36%$87.26Mvs ANIX
OGIOrganigram Global Inc.0.583-7.40%$82.27Mvs ANIX
HURATuHURA Biosciences Inc.1.25-8.09%$82.20Mvs ANIX
RTSNRetension Pharmaceuticals Inc.10.51-19.22%$87.57Mvs ANIX
CPIXCumberland Pharmaceuticals Inc.5.84-7.30%$87.57Mvs ANIX
NKTXNkarta Inc.1.14+1.34%$81.29Mvs ANIX
TLSATiziana Life Sciences Ltd.0.6206-8.14%$79.45Mvs ANIX

Indexes, lists and sector

Anixa Biosciences stock FAQ

What is Anixa Biosciences's stock price today?

ANIX last traded at $2.44 as of Nov 20, 4:00 PM EST, down 6.15% on the day. Prices are delayed at least 15 minutes.

Does Anixa Biosciences pay a dividend?

No. Anixa Biosciences does not currently pay a regular cash dividend.

Who is Anixa Biosciences's CEO?

Dr. Amit Kumar Ph.D. is the chief executive officer of Anixa Biosciences Inc., which has about 4 employees.

Has ANIX ever split its stock?

Yes. The most recent ANIX stock split was a 1-for-25 split on Jun 26, 2015, one of 5 splits on record.

What is the ANIX 52-week high?

The 52-week high for ANIX is $5.46 and the 52-week low is $2.32. The stock is currently 55.3% below its high.

Compare ANIX